PTC Therapeutics (PTCT) Misses Q2 EPS by 11c

PTC Therapeutics (NASDAQ: PTCT) reported Q2 EPS of ($0.86), $0.11 worse than the analyst estimate of ($0.75). Revenue for the quarter came in at $1.7 million versus the consensus estimate of $1.71 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• JPMorgan Upgrades SHIFT UP Corp (462870:KS) to Overweight
• Hyperscale Data launches $300M at-the-market stock offering